Please check your internet connection and try again.
# L-Ornithine L-Aspartate
## Overview
L-ornithine L-aspartate (LOLA) is a combination of two amino acids, ornithine and aspartate, that are involved in the urea cycle and ammonia detoxification. It is primarily used in the management of hyperammonemia associated with liver disease.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy (HE).
* Reduction of elevated blood ammonia levels in patients with liver dysfunction.
## Adult Dosing
* **Oral:** 3-6 grams three times daily. Maximum daily dose is typically 18 grams.
* **Intravenous (IV):** 5-10 grams twice daily, diluted in 500 mL of dextrose 5% or 0.9% sodium chloride. Total daily dose usually 10-20 grams. The specific rate of infusion should follow local protocol but is often administered over 30-60 minutes.
## Pediatric Dosing
* There is limited data for pediatric use. Dosing in children should be based on the severity of the condition and the patient's response, and guided by specialist recommendations. Some sources suggest oral doses of 5-10 mL (equivalent to approximately 1-2 grams of LOLA) three times daily for children, but this is not well-established.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment beyond the underlying disease management. However, caution is advised in patients with severe renal impairment due to potential accumulation of the amino acids.
## Contraindications
* Severe hypersensitivity to L-ornithine or L-aspartate.
* Patients with severe renal failure (creatinine clearance < 25 mL/min) should generally avoid or use with extreme caution due to potential accumulation.
* Avoid in patients with homozygous familial hyperprolinemia.
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal discomfort, diarrhea.
* **Less Common:** Drowsiness, headache, muscle weakness, rash, itching.
* **Rare:** Bronchospasm (especially with IV administration).
## Key Drug Interactions
* No significant drug interactions are well-documented.
## Monitoring
* **Ammonia levels:** Monitor blood ammonia levels to assess efficacy.
* **Hepatic encephalopathy symptoms:** Clinical assessment for improvement in neurological status.
* **Renal function:** Monitor electrolytes and renal function, especially in patients with pre-existing renal compromise.
## Clinical Pearls
* LOLA works by promoting ammonia detoxification in the liver and brain. Ornithine stimulates the urea cycle, and aspartate facilitates ammonia removal through glutamine synthesis.
* Oral administration can be given with or without food.
* IV administration should be done slowly and diluted to minimize local irritation and potential adverse effects.
***
*Please consult the most current prescribing information for detailed guidance. This information is intended for healthcare professionals and does not substitute for professional medical judgment.*
